114 related articles for article (PubMed ID: 7704209)
21. Determination of Liposomal Cisplatin by High-Performance Liquid Chromatography and Its Application in Pharmacokinetic Studies.
Toro-Córdova A; Ledezma-Gallegos F; Mondragon-Fuentes L; Jurado R; Medina LA; Pérez-Rojas JM; Garcia-Lopez P
J Chromatogr Sci; 2016 Jul; 54(6):1016-21. PubMed ID: 27013666
[TBL] [Abstract][Full Text] [Related]
22. Effects of disopyramide and verapamil on renal disposition and nephrotoxicity of cisplatin in rats.
Hanada K; Odaka K; Kudo A; Ogata H
Pharm Res; 1999 Oct; 16(10):1589-95. PubMed ID: 10554102
[TBL] [Abstract][Full Text] [Related]
23. A model for ultrafilterable plasma platinum disposition in patients treated with cisplatin.
Reece PA; Stafford I; Russell J; Khan M; Gill PG
Cancer Chemother Pharmacol; 1987; 20(1):26-32. PubMed ID: 3621450
[TBL] [Abstract][Full Text] [Related]
24. Separation and quantitation of metallothioneins by high-performance liquid chromatography coupled with atomic absorption spectrophotometry.
Lehman LD; Klaassen CD
Anal Biochem; 1986 Mar; 153(2):305-14. PubMed ID: 3706713
[TBL] [Abstract][Full Text] [Related]
25. High-performance liquid chromatographic determination of cisplatin as platinum(II) in a pharmaceutical preparation and blood samples of cancer patients.
Khuhawar MY; Lanjwani SN; Memon SA
J Chromatogr B Biomed Sci Appl; 1997 May; 693(1):175-9. PubMed ID: 9200532
[TBL] [Abstract][Full Text] [Related]
26. Cisplatin-induced loss of kidney copper and nephrotoxicity is ameliorated by single dose diethyldithiocarbamate, but not mesna.
DeWoskin RS; Riviere JE
Toxicol Appl Pharmacol; 1992 Feb; 112(2):182-9. PubMed ID: 1311464
[TBL] [Abstract][Full Text] [Related]
27. Determination of cisplatin and some possible metabolites by ion-pairing chromatography with inductively coupled plasma mass spectrometric detection.
Zhao Z; Tepperman K; Dorsey JG; Elder RC
J Chromatogr; 1993 May; 615(1):83-9. PubMed ID: 8340466
[TBL] [Abstract][Full Text] [Related]
28. Simultaneous determination of ten anticoagulant rodenticides in tissues by column-switching UHPLC-ESI-MS/MS.
Maršálek P; Modrá H; Doubková V; Večerek V
Anal Bioanal Chem; 2015 Oct; 407(25):7849-54. PubMed ID: 26280206
[TBL] [Abstract][Full Text] [Related]
29. HPLC determination of cis-diamminedichloroplatinum(II) in plasma and urine with UV detection and column-switching.
Kizu R; Hayakawa K; Miyazaki M
Biomed Chromatogr; 1989 Jan; 3(1):14-9. PubMed ID: 2706360
[TBL] [Abstract][Full Text] [Related]
30. A novel method for speciation of Pt in human serum incubated with cisplatin, oxaliplatin and carboplatin by conjoint liquid chromatography on monolithic disks with UV and ICP-MS detection.
Martinčič A; Cemazar M; Sersa G; Kovač V; Milačič R; Ščančar J
Talanta; 2013 Nov; 116():141-8. PubMed ID: 24148385
[TBL] [Abstract][Full Text] [Related]
31. [Experimental studies on drug concentrations in the liver using intra-hepatic injection of anticancer drug in combination with temporary halting of abdominal blood flow].
Nishioka Y; Iwama T; Ishida H; Fukunari H; Yamazaki T; Okubo Y; Imajo M; Mishima Y; Endo S
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 2):1736-9. PubMed ID: 2389961
[TBL] [Abstract][Full Text] [Related]
32. [Pharmacokinetics of cisplatin and the effect of sodium thiosulfate].
Hayata S; Hitoshi T; Kiyokawa K; Esaki S; Mihashi S; Hirano M
Gan To Kagaku Ryoho; 1984 Nov; 11(11):2356-61. PubMed ID: 6541891
[TBL] [Abstract][Full Text] [Related]
33. Development and validation of an UPLC-MS/MS method for the quantification of irinotecan, SN-38 and SN-38 glucuronide in plasma, urine, feces, liver and kidney: Application to a pharmacokinetic study of irinotecan in rats.
Basu S; Zeng M; Yin T; Gao S; Hu M
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Mar; 1015-1016():34-41. PubMed ID: 26894853
[TBL] [Abstract][Full Text] [Related]
34. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients.
Nagai N; Kinoshita M; Ogata H; Tsujino D; Wada Y; Someya K; Ohno T; Masuhara K; Tanaka Y; Kato K; Nagai H; Yokoyama A; Kurita Y
Cancer Chemother Pharmacol; 1996; 39(1-2):131-7. PubMed ID: 8995510
[TBL] [Abstract][Full Text] [Related]
35. Recent advances in high-performance liquid chromatography/mass spectrometry and high-performance liquid chromatography/tandem mass spectrometry: detection of cyclosporine and metabolites in kidney and liver tissue.
Whitman DA; Abbott V; Fregien K; Bowers LD
Ther Drug Monit; 1993 Dec; 15(6):552-6. PubMed ID: 8122293
[TBL] [Abstract][Full Text] [Related]
36. Kinetic study of the reaction of cisplatin with thiols.
Dabrowiak JC; Goodisman J; Souid AK
Drug Metab Dispos; 2002 Dec; 30(12):1378-84. PubMed ID: 12433807
[TBL] [Abstract][Full Text] [Related]
37. In vivo pharmacokinetic and tissue distribution investigation of sustained-release cisplatin implants in the normal esophageal submucosa of 12 beagle dogs.
Yin JX; Wei Z; Xu JJ; Sun ZQ
Cancer Chemother Pharmacol; 2015 Sep; 76(3):525-36. PubMed ID: 26183605
[TBL] [Abstract][Full Text] [Related]
38. The renal clearance of unchanged cisplatin during furosemide and mannitol diuresis is dependent on glomerular filtration rate in rats.
Nagai N; Ogata H
J Pharm Sci; 1996 Jul; 85(7):720-4. PubMed ID: 8818996
[TBL] [Abstract][Full Text] [Related]
39. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
Gao J; Meng Q; Zhao Y; Chen X; Cai L
BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
[TBL] [Abstract][Full Text] [Related]
40. Preparation, characterization and in vivo distribution of solid lipid nanoparticles loaded with cisplatin.
Tian J; Pang X; Yu K; Liu L; Zhou J
Pharmazie; 2008 Aug; 63(8):593-7. PubMed ID: 18771008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
